GSK Plc Updates on Drug Pipeline and Clinical Trials
GSK plc provided an overview of its drug development pipeline, detailing numerous candidates across various therapeutic areas. The update includes progress on vaccines and medicines in Phase I through Registration.
GSK plc, a global biopharmaceutical company, has released an update on its research and development pipeline, highlighting progress in clinical trials for a range of new vaccines and medicines. The company's portfolio includes 70 potential new treatments across oncology, respiratory, immunology, inflammation, and infectious diseases.
The pipeline features 23 candidates in Phase III or registration, including treatments like camlipixant for P2X3 receptor antagonism and depemokimab, a long-acting anti-IL5 antibody. Other late-stage candidates include belrestotug (anti-TIGIT antibody), Blenrep (anti-BCMA ADC), and the RSV vaccine Arexvy.
In Phase II development, GSK has listed 26 potential treatments, such as Benlysta for autoimmune conditions and several novel antibody and small molecule inhibitors. The company is also advancing vaccine candidates, including recombinant protein and mRNA-based technologies for various infectious diseases.
Furthermore, GSK's Phase I pipeline comprises 29 candidates targeting conditions from sickle cell disease and autoimmune disorders to HIV and malaria. This includes investigational treatments like XMT-2056, a STING agonist ADC, and various antibody-drug conjugates and small molecule inhibitors.
The update underscores GSK's ongoing commitment to advancing medical innovation. The company's diverse pipeline reflects its strategy to address significant unmet medical needs across multiple disease areas.